Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group

What Was Tested

The paper reports a study of ANP (Atrial Natriuretic Peptide), published as a randomized controlled trial.

Who Took Part

The study group was 504 patients.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got ANP (Atrial Natriuretic Peptide) and who got the comparison, which limits bias.

As a double-blind ANP (Atrial Natriuretic Peptide) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the ANP (Atrial Natriuretic Peptide) group a baseline to be compared against.

More than one site took part, so the patients came from several places.

The methods mention a period of 60 days.

Dialysis and mortality status were followed up for 60 days.

What Was Measured

Topics PubMed links to this paper include Atrial Natriuretic Factor, Blood Pressure, Data Interpretation, Statistical, Diuretics, Heart Rate, Kidney Tubular Necrosis, Acute and Oliguria.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of ANP (Atrial Natriuretic Peptide) in 504 patients over 60 days.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2000 (American journal of kidney diseases : the official journal of the National Kidney Foundation), a journal based in United States.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.